10-Q: CorMedix Q3 2025: Melinta Acquisition Fuels Revenue Surge

CorMedix Inc. reports a significant revenue increase in Q3 2025, driven by strong DefenCath sales and the strategic acquisition of Melinta Therapeutics, despite ongoing legal challenges and increased operating expenses.

Summary

• Net income for the three months ended September 30, 2025, was $108.6 million, a significant turnaround from a net loss of $(2.8) million in the same period of 2024.
• Net income for the nine months ended September 30, 2025, was $149.0 million, compared to a net loss of $(31.4) million in the prior year period.
• Total Revenue for Q3 2025 reached $104.3 million, an 810% increase from $11.5 million in Q3 2024.
• Year-to-date Total Revenue for 2025 was $183.1 million, a 1,393% increase from $12.3 million in 2024.
• DefenCath product sales contributed $88.8 million in Q3 2025 and $167.6 million year-to-date 2025.
• The acquisition of Melinta Therapeutics, LLC closed on August 29, 2025, for $260 million in cash and $40 million in common shares, expanding the commercial portfolio with six infectious disease products and one cardiovascular product.
• Melinta Portfolio product sales accounted for $12.8 million from the acquisition date through September 30, 2025.
• The company recognized a $59.7 million income tax benefit in Q3 2025 due to the release of a $280.0 million valuation allowance on deferred tax assets.
• Cash and cash equivalents stood at $48.5 million as of September 30, 2025, up from $40.7 million at December 31, 2024.
• Total assets increased to $750.9 million as of September 30, 2025, from $118.8 million at December 31, 2024, largely due to the Melinta acquisition.
• Total liabilities rose to $376.7 million as of September 30, 2025, from $34.2 million at December 31, 2024, including $144.5 million in convertible senior notes.
• Issued $150 million aggregate principal amount of 4.00% Convertible Senior Notes due 2030.
• Shareholders approved an amendment to increase the number of shares available for issuance under the 2019 Omnibus Stock Incentive Plan from 8,160,000 to 12,472,000.
• Shareholders did not approve the ratification of Series E Preferred Stock Certificate of Designation amendments or the Certificate of Incorporation Amendment Proposal.
• A change in estimate for Medicaid and commercial rebates negatively impacted net sales, income from continuing operations, and net income by $1.7 million for the nine months ended September 30, 2025.
• Ongoing legal proceedings include securities litigation, derivative litigation, and Melinta's MINOCIN patent litigation.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround with significant revenue growth and net income, largely due to the successful commercial launch of DefenCath and the strategic Melinta acquisition. The expanded product portfolio, favorable reimbursement for DefenCath, and significant government funding potential from the BARDA agreement are highly positive. While operating expenses increased due to the acquisition and legal proceedings are ongoing, the overall strategic execution and financial performance indicate a strong growth trajectory.

Positives

• Achieved significant net income of $108.6 million in Q3 2025, a substantial improvement from a net loss in the prior year.
• Reported exceptional revenue growth of 810% in Q3 2025 and 1,393% year-to-date, driven by strong product commercialization.
• DefenCath sales were robust, contributing $88.8 million in Q3 2025 and $167.6 million year-to-date.
• The strategic acquisition of Melinta Therapeutics expanded the product portfolio with six marketed infectious disease products and one cardiovascular product, diversifying revenue streams and commercial reach.
• Recognized a substantial income tax benefit of $59.7 million from the release of a $280.0 million valuation allowance on deferred tax assets, indicating improved financial health and future profitability expectations.
• Maintained a strong cash position with $55.7 million in cash and short-term investments as of September 30, 2025.
• DefenCath holds New Chemical Entity (NCE) exclusivity until November 15, 2028, and a GAIN exclusivity extension until November 15, 2033, providing market protection.
• DefenCath qualified for Transitional Drug Add-on Payment Adjustment (TDAPA) and New Technology Add-On Payment (NTAP), ensuring favorable reimbursement mechanisms.
• The BARDA agreement provides potential funding of up to $144.6 million for the development of Baxdela and Vabomere for pediatric use and biothreat pathogens.
• Shareholders approved an increase in shares for the Omnibus Stock Incentive Plan, supporting employee incentives and talent retention.

Negatives

• Operating expenses increased significantly, with R&D up 601% and G&A up 287% in Q3 2025, primarily due to the Melinta acquisition and related transaction costs.
• Cost of sales increased by 1,092% in Q3 2025, driven by higher product sales and amortization of acquired intangible assets.
• Interest expense rose to $0.9 million in Q3 2025 from minimal amounts in the prior year, due to the issuance of convertible senior notes.
• A change in estimate for Medicaid and commercial rebates negatively impacted net income by $1.7 million for the nine months ended September 30, 2025.
• Shareholders did not approve two corporate governance proposals: the ratification of Series E Preferred Stock Certificate of Designation amendments and the Certificate of Incorporation Amendment Proposal.
• The contingent consideration liability increased by $2.4 million in Q3 2025, primarily due to a lower discount rate and accretion from the passage of time.
• Ongoing legal proceedings, including securities litigation, derivative litigation, and patent litigation for MINOCIN, pose potential financial and reputational risks.

Risks

• Inability to successfully integrate CorMedix and Melinta businesses and realize anticipated synergies or benefits within expected timeframes.
• Integration process may be more difficult, time-consuming, or costly than expected, leading to higher operating costs, customer loss, and business disruption.
• Unexpected departure of key personnel from Melinta post-acquisition.
• Underperformance of Melinta's business relative to expectations, including potential loss of customer relationships.
• Adverse effects from tariffs, trade sanctions, or similar government actions, particularly on pharmaceutical imports from Europe, increasing costs and reducing profitability.
• Clinical trials required for product lines may be expensive, time-consuming, and have uncertain outcomes, with potential for delays, lack of effectiveness, or unforeseen safety issues.
• Interim, topline, and preliminary clinical trial data may change as more patient data become available, leading to different final results or conclusions.
• Development of bacterial resistance to products or product candidates, which would decrease their efficacy and commercial viability.
• Risk of improper promotion of off-label uses, leading to regulatory sanctions, significant fines, penalties, or product liability claims.
• Dependence on ongoing funding decisions by the U.S. Government for the BARDA development contract, with potential for reduction or discontinuation of funding.
• Reliance on third-party suppliers and contract manufacturers for product supply and APIs, which subjects the company to potential cost increases, manufacturing delays, and risks associated with technology transfers.
• Uncertain timing of milestone and royalty payments required to be made to third parties, which could adversely affect cash flows and results of operations.
• Adverse outcome in the ongoing MINOCIN (minocycline) for Injection patent litigation, which could allow generic entry and materially harm the business.
• Ability to pursue the development and commercialization of certain products depends upon the continuation of certain licenses and actions taken by license partners (e.g., REZZAYO).
• Disputes may arise regarding intellectual property subject to licensing agreements, potentially narrowing rights or increasing financial obligations.

Future Outlook

The company expects to fund its operations for the next 12 months with existing cash and investments, supplemented by additional cash flow from future operating activities. The completion of the Phase III study for REZZAYO is anticipated in 2026. The BARDA contract, if all options are exercised, is projected to continue through 2034, potentially providing up to $144.6 million in funding. The company aims to submit four supplemental New Drug Applications (sNDAs) for Baxdela and Vabomere for pediatric use.

Management Comments

• Expect to fund operations for the next 12 months with cash and investments on hand at September 30, 2025, of approximately $55.7 million, as well as additional cash flow from future operating activities.

Industry Context

The acquisition of Melinta Therapeutics significantly expands CorMedix's footprint in the hospital and clinic-focused infectious disease market, diversifying its product portfolio beyond its lead product, DefenCath. This strategic move positions the company with a broader range of marketed products and ongoing R&D, including the Phase III study for REZZAYO. The BARDA agreement highlights engagement with government initiatives for biodefense and pediatric indications, a common strategy for biopharmaceutical companies. The ongoing patent litigation for MINOCIN reflects typical industry challenges in defending intellectual property against generic competition.

Comparison to Industry Standards

• DefenCath is the first and only FDA-approved antimicrobial catheter lock solution (CLS) in the U.S., demonstrating a significant competitive advantage in its niche by reducing the risk of catheter-related bloodstream infections (CRBSI) by up to 71% in a Phase 3 clinical study.
• The acquisition of Melinta's portfolio, including REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL, positions CorMedix with a broader range of marketed hospital-focused infectious disease products, comparable to mid-sized specialty pharmaceutical companies aiming for market diversification.
• REZZAYO's ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation represents a standard development pathway for expanding the indications of an already approved drug.
• The BARDA contract for Baxdela and Vabomere for pediatric use and biothreat pathogens aligns with public health priorities and government funding opportunities frequently pursued by companies in the infectious disease space to de-risk and accelerate development.

Corporate Governance

Legal Proceedings

• In re CorMedix Inc. Securities Litigation, Case No. 2:21-cv-14020 (D.N.J.): A consolidated class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Exchange Act, along with Rule 10b-5, related to DefenCath NDA submissions, complete response letters, and FDA communications regarding the company's contract manufacturing organization and heparin supplier. The motion to dismiss was denied on August 19, 2025, and the case has proceeded to discovery, with mediation scheduled for November 18, 2025.
• In re CorMedix Inc. Derivative Litigation, C.A. No. 2:21-cv-18493-JXN-LDW (D.N.J.): A consolidated shareholder derivative action alleging breaches of fiduciary duties, abuse of control, and waste of corporate assets against individual defendants, with similar allegations to the securities class action. A verified consolidated shareholder derivative complaint was filed on November 10, 2025, and parties are to meet and confer on a case schedule by November 24, 2025.
• Raval v. Baluch, Case No. UNN-L-003721-25 (N.J. Super Ct. Law Div.): A shareholder derivative complaint filed on September 26, 2025, with similar allegations to the federal derivative litigation. A Stipulation and Consent Order was entered on October 22, 2025, providing the plaintiff until December 4, 2025, to file an amended complaint or designate it as operative.
• Melinta Legal Proceedings (MINOCIN patent litigation): Melinta is involved in patent litigation for MINOCIN (minocycline) for Injection. In November 2024, a permanent injunction was issued against Nexus Pharmaceuticals' ANDA, which Nexus has appealed to the U.S. Court of Appeals for the Federal Circuit. Additionally, Melinta filed a suit against Gland Pharma in April 2025 following a PIV certification for MINOCIN patents in February 2025.

Related Party Transactions

• During the fourth quarter of 2025, the company's CEO was appointed to the Board of Directors of Talphera, Inc., a publicly traded biotechnology company in which CorMedix holds marketable equity securities, making Talphera a related party in subsequent periods.

Stakeholder Impact

• Shareholders: Experienced significant positive impact from strong financial performance, strategic acquisition, and tax benefits, but also face potential dilution from capital raises and risks from ongoing legal proceedings.
• Employees: Impacted by severance costs due to position eliminations post-Melinta merger, but also benefit from increased shares available for the stock incentive plan.
• Customers: Benefit from an expanded product portfolio (Melinta) and continued commercialization of DefenCath with favorable reimbursement status (TDAPA, NTAP).
• Suppliers/Manufacturers: Continued reliance on third-party manufacturers, with efforts to qualify alternate suppliers and onshore manufacturing, indicating ongoing business for these partners.
• Creditors: The issuance of Convertible Senior Notes increases debt obligations, but the company's improved financial health may enhance its creditworthiness.

Next Steps

• Complete the Phase III study for REZZAYO, expected in 2026.
• Qualify an alternate third-party supplier for heparin sodium API over the next twelve months.
• Scale up production at Siegfried Hameln as an alternate finished dosage manufacturing site.
• Complete ongoing technology transfers to reduce costs of goods sold and onshore manufacturing over the next two to three years.
• Submit four supplemental New Drug Applications (sNDAs) for Baxdela and Vabomere for pediatric use.
• Attend mediation scheduled for November 18, 2025, for In re CorMedix Inc. Securities Litigation.
• Meet and confer on a case schedule for In re CorMedix Inc. Derivative Litigation on or before November 24, 2025.
• Plaintiff in Raval v. Baluch to file an amended complaint or designate the complaint as operative by December 4, 2025.
• Substantially complete document production for securities litigation by January 27, 2026.
• Complete fact discovery for securities litigation by June 25, 2026.
• Complete expert discovery for securities litigation by December 28, 2026.
• Continue to evaluate the realizability of remaining deferred tax assets each reporting period.
• Pay all severance associated with the Merger by December 31, 2026.
• Receive committed API deliveries for VABOMERE in Q4 2025 and Q4 2026.

Key Dates

Recommendation

The company has demonstrated a remarkable financial turnaround, achieving substantial net income and revenue growth driven by the successful commercial launch of DefenCath and the strategic acquisition of Melinta Therapeutics. The expanded product portfolio in infectious diseases, coupled with favorable reimbursement for DefenCath and significant government funding potential from the BARDA agreement, positions the company for continued growth. The release of a large deferred tax asset valuation allowance further strengthens its financial outlook. While legal proceedings and integration risks exist, the overall strategic execution and financial performance indicate a strong growth trajectory, making it an attractive investment.

Keywords

Biopharmaceutical, DefenCath, Melinta Therapeutics, REZZAYO, MINOCIN, Infectious Disease, FDA Approval, Acquisition, Convertible Notes, Clinical Trials, Patent Litigation, Corporate Governance, Risk Factors, Commercialization, Hemodialysis, Catheter-Related Bloodstream Infections, Antimicrobial, QIDP, TDAPA, NTAP, BARDA, Financial Results